Global Renal Denervation (RDN) Therapy 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI06262832

Publication Date:

June 16, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global Renal Denervation (RDN) Therapy market size is predicted to grow from US$ 2148 million in 2025 to US$ 14680 million in 2031; it is expected to grow at a CAGR of 37.8% from 2025 to 2031.
United States market for Renal Denervation (RDN) Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Renal Denervation (RDN) Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Renal Denervation (RDN) Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Renal Denervation (RDN) Therapy players cover Medtronic (Covidien), ReCor, Johnson & Johnson, Boston Scientific, Shanghai Golden Leaf Med Tec Co., Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淩enal Denervation (RDN) Therapy Industry Forecast鈥� looks at past sales and reviews total world Renal Denervation (RDN) Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Renal Denervation (RDN) Therapy sales for 2025 through 2031. With Renal Denervation (RDN) Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Renal Denervation (RDN) Therapy industry.
This Insight Report provides a comprehensive analysis of the global Renal Denervation (RDN) Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Renal Denervation (RDN) Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Renal Denervation (RDN) Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Renal Denervation (RDN) Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Renal Denervation (RDN) Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of Renal Denervation (RDN) Therapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
Radio Frequency
Ultrasonic
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Medtronic (Covidien)
ReCor
Johnson & Johnson
Boston Scientific
Shanghai Golden Leaf Med Tec Co., Ltd
Bio-Heart
SyMap Medical
Venus Medtech
Shanghai Microport Ep Medtech Co.,Ltd.
Cryofocus Medtech

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Renal Denervation (RDN) Therapy 麻豆原创 Size (2020-2031)
2.1.2 Renal Denervation (RDN) Therapy 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Renal Denervation (RDN) Therapy by Country/Region (2020, 2024 & 2031)
2.2 Renal Denervation (RDN) Therapy Segment by Type
2.2.1 Radio Frequency
2.2.2 Ultrasonic
2.3 Renal Denervation (RDN) Therapy 麻豆原创 Size by Type
2.3.1 Renal Denervation (RDN) Therapy 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Renal Denervation (RDN) Therapy 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Renal Denervation (RDN) Therapy Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Renal Denervation (RDN) Therapy 麻豆原创 Size by Application
2.5.1 Renal Denervation (RDN) Therapy 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Renal Denervation (RDN) Therapy 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Renal Denervation (RDN) Therapy 麻豆原创 Size by Player
3.1 Renal Denervation (RDN) Therapy 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Renal Denervation (RDN) Therapy Revenue by Player (2020-2025)
3.1.2 Global Renal Denervation (RDN) Therapy Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Renal Denervation (RDN) Therapy Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Renal Denervation (RDN) Therapy by Region
4.1 Renal Denervation (RDN) Therapy 麻豆原创 Size by Region (2020-2025)
4.2 Global Renal Denervation (RDN) Therapy Annual Revenue by Country/Region (2020-2025)
4.3 Americas Renal Denervation (RDN) Therapy 麻豆原创 Size Growth (2020-2025)
4.4 APAC Renal Denervation (RDN) Therapy 麻豆原创 Size Growth (2020-2025)
4.5 Europe Renal Denervation (RDN) Therapy 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Renal Denervation (RDN) Therapy 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Renal Denervation (RDN) Therapy 麻豆原创 Size by Country (2020-2025)
5.2 Americas Renal Denervation (RDN) Therapy 麻豆原创 Size by Type (2020-2025)
5.3 Americas Renal Denervation (RDN) Therapy 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Renal Denervation (RDN) Therapy 麻豆原创 Size by Region (2020-2025)
6.2 APAC Renal Denervation (RDN) Therapy 麻豆原创 Size by Type (2020-2025)
6.3 APAC Renal Denervation (RDN) Therapy 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Renal Denervation (RDN) Therapy 麻豆原创 Size by Country (2020-2025)
7.2 Europe Renal Denervation (RDN) Therapy 麻豆原创 Size by Type (2020-2025)
7.3 Europe Renal Denervation (RDN) Therapy 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Renal Denervation (RDN) Therapy by Region (2020-2025)
8.2 Middle East & Africa Renal Denervation (RDN) Therapy 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Renal Denervation (RDN) Therapy 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Renal Denervation (RDN) Therapy 麻豆原创 Forecast
10.1 Global Renal Denervation (RDN) Therapy Forecast by Region (2026-2031)
10.1.1 Global Renal Denervation (RDN) Therapy Forecast by Region (2026-2031)
10.1.2 Americas Renal Denervation (RDN) Therapy Forecast
10.1.3 APAC Renal Denervation (RDN) Therapy Forecast
10.1.4 Europe Renal Denervation (RDN) Therapy Forecast
10.1.5 Middle East & Africa Renal Denervation (RDN) Therapy Forecast
10.2 Americas Renal Denervation (RDN) Therapy Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.2.2 Canada 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.2.3 Mexico 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.2.4 Brazil 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.3 APAC Renal Denervation (RDN) Therapy Forecast by Region (2026-2031)
10.3.1 China Renal Denervation (RDN) Therapy 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.3.3 Korea 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.3.4 Southeast Asia 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.3.5 India 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.3.6 Australia 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.4 Europe Renal Denervation (RDN) Therapy Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.4.2 France 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.4.3 UK 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.4.4 Italy 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.4.5 Russia 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.5 Middle East & Africa Renal Denervation (RDN) Therapy Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.5.2 South Africa 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.5.3 Israel 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.5.4 Turkey 麻豆原创 Renal Denervation (RDN) Therapy Forecast
10.6 Global Renal Denervation (RDN) Therapy Forecast by Type (2026-2031)
10.7 Global Renal Denervation (RDN) Therapy Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Renal Denervation (RDN) Therapy Forecast
11 Key Players Analysis
11.1 Medtronic (Covidien)
11.1.1 Medtronic (Covidien) Company Information
11.1.2 Medtronic (Covidien) Renal Denervation (RDN) Therapy Product Offered
11.1.3 Medtronic (Covidien) Renal Denervation (RDN) Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Medtronic (Covidien) Main Business Overview
11.1.5 Medtronic (Covidien) Latest Developments
11.2 ReCor
11.2.1 ReCor Company Information
11.2.2 ReCor Renal Denervation (RDN) Therapy Product Offered
11.2.3 ReCor Renal Denervation (RDN) Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 ReCor Main Business Overview
11.2.5 ReCor Latest Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Information
11.3.2 Johnson & Johnson Renal Denervation (RDN) Therapy Product Offered
11.3.3 Johnson & Johnson Renal Denervation (RDN) Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Johnson & Johnson Main Business Overview
11.3.5 Johnson & Johnson Latest Developments
11.4 Boston Scientific
11.4.1 Boston Scientific Company Information
11.4.2 Boston Scientific Renal Denervation (RDN) Therapy Product Offered
11.4.3 Boston Scientific Renal Denervation (RDN) Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Boston Scientific Main Business Overview
11.4.5 Boston Scientific Latest Developments
11.5 Shanghai Golden Leaf Med Tec Co., Ltd
11.5.1 Shanghai Golden Leaf Med Tec Co., Ltd Company Information
11.5.2 Shanghai Golden Leaf Med Tec Co., Ltd Renal Denervation (RDN) Therapy Product Offered
11.5.3 Shanghai Golden Leaf Med Tec Co., Ltd Renal Denervation (RDN) Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Shanghai Golden Leaf Med Tec Co., Ltd Main Business Overview
11.5.5 Shanghai Golden Leaf Med Tec Co., Ltd Latest Developments
11.6 Bio-Heart
11.6.1 Bio-Heart Company Information
11.6.2 Bio-Heart Renal Denervation (RDN) Therapy Product Offered
11.6.3 Bio-Heart Renal Denervation (RDN) Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Bio-Heart Main Business Overview
11.6.5 Bio-Heart Latest Developments
11.7 SyMap Medical
11.7.1 SyMap Medical Company Information
11.7.2 SyMap Medical Renal Denervation (RDN) Therapy Product Offered
11.7.3 SyMap Medical Renal Denervation (RDN) Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 SyMap Medical Main Business Overview
11.7.5 SyMap Medical Latest Developments
11.8 Venus Medtech
11.8.1 Venus Medtech Company Information
11.8.2 Venus Medtech Renal Denervation (RDN) Therapy Product Offered
11.8.3 Venus Medtech Renal Denervation (RDN) Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Venus Medtech Main Business Overview
11.8.5 Venus Medtech Latest Developments
11.9 Shanghai Microport Ep Medtech Co.,Ltd.
11.9.1 Shanghai Microport Ep Medtech Co.,Ltd. Company Information
11.9.2 Shanghai Microport Ep Medtech Co.,Ltd. Renal Denervation (RDN) Therapy Product Offered
11.9.3 Shanghai Microport Ep Medtech Co.,Ltd. Renal Denervation (RDN) Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Shanghai Microport Ep Medtech Co.,Ltd. Main Business Overview
11.9.5 Shanghai Microport Ep Medtech Co.,Ltd. Latest Developments
11.10 Cryofocus Medtech
11.10.1 Cryofocus Medtech Company Information
11.10.2 Cryofocus Medtech Renal Denervation (RDN) Therapy Product Offered
11.10.3 Cryofocus Medtech Renal Denervation (RDN) Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Cryofocus Medtech Main Business Overview
11.10.5 Cryofocus Medtech Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.